GALT NASDAQ
Galectin Therapeutics Inc.
1W: +0.0%
1M: -12.9%
3M: -15.8%
YTD: -3.7%
1Y: -6.7%
3Y: +115.5%
5Y: -6.0%
$3.90
+0.14 (+3.72%)
Weekly Expected Move ±8.1%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (34)
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average – Here’s What Happened
Galectin Therapeutics reports Q2 results
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
12 Health Care Stocks Moving In Friday's After-Market Session
Galectin Therapeutics GAAP EPS of -$0.08 misses by $0.02
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
12 Health Care Stocks Moving In Tuesday's After-Market Session
FY2026 Earnings Forecast for GALT Issued By HC Wainwright
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
What is HC Wainwright’s Estimate for GALT Q1 Earnings?
Galectin Therapeutics GAAP EPS of -$0.48 beats by $0.01
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis